MXC Stock Overview
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide.
MGC Pharmaceuticals Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.012|
|52 Week High||AU$0.05|
|52 Week Low||AU$0.012|
|1 Month Change||-11.11%|
|3 Month Change||-25.00%|
|1 Year Change||-70.73%|
|3 Year Change||-63.64%|
|5 Year Change||-84.00%|
|Change since IPO||-91.72%|
Recent News & Updates
MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?Jun 23
MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?Mar 09
Auditors Have Doubts About MGC Pharmaceuticals (ASX:MXC)Oct 08
If You Had Bought MGC Pharmaceuticals (ASX:MXC) Shares A Year Ago You'd Have Earned 346% ReturnsFeb 21
What Does MGC Pharmaceuticals' (ASX:MXC) CEO Pay Reveal?Dec 30
|MXC||AU Pharmaceuticals||AU Market|
Return vs Industry: MXC underperformed the Australian Pharmaceuticals industry which returned -23.7% over the past year.
Return vs Market: MXC underperformed the Australian Market which returned -1.8% over the past year.
|MXC Average Weekly Movement||10.9%|
|Pharmaceuticals Industry Average Movement||10.2%|
|Market Average Movement||8.9%|
|10% most volatile stocks in AU Market||15.9%|
|10% least volatile stocks in AU Market||4.1%|
Stable Share Price: MXC is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: MXC's weekly volatility (11%) has been stable over the past year.
About the Company
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia.
MGC Pharmaceuticals Limited Fundamentals Summary
|MXC fundamental statistics|
Is MXC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MXC income statement (TTM)|
|Cost of Revenue||AU$4.17m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.007|
|Net Profit Margin||-430.00%|
How did MXC perform over the long term?See historical performance and comparison